Myr-EL17 restored the platelet function affected by myr-KF7 and THO. (A-F) Washed human platelets (300 × 109/L) were preincubated with myr-KF7 (A-C) or THO (D-F) with various concentrations of myr-EL17. Aggregations were elicited by thrombin (0.03 U/mL), collagen (1 μg/mL), or anti-αIIb TM peptide (1 μM). (G) Washed human platelets (100 × 109/L) were preincubated with 50 μM myr-KF7 or THO in the presence of 100 μM myr-EL17 or myr-EL17scr (both 100 μM). After 40 minutes of spreading on immobilized fibrinogen at 37°C, the platelets were stained with FITC-conjugated phalloidin for immunofluorescence microscopy. myr-EL17 and myr-EL17scr (both 100 μM) and 10 μM eptifibatide were used as the controls. The bar represents 10 μm. (H) Image J software was used to quantify the number of platelets and area of spread. (I) Platelets preincubated with 30 μM myr-KF7 and THO in the presence of 90 μM myr-EL17 or myr-EL17scr were activated by thrombin (0.03 U/mL), collagen (1 μg/mL), or anti-αIIb TM peptide (1 μM), and the cell lysates were immunoblotted with Src pY416 and c-Src antibodies. (J) Western blot analysis of the recombinant c-Src and 14-3-3ζ precipitated by biotin-conjugated β3CT in the presence of 30 μM KF7 or THO, with or without 90 μM EL17. All data are expressed as means ± SD (n = 3). *P < .05; **P < .01; ***P < .001.